Program-Level Restrictions

A more serious but still sector-contained path is that U.S. agencies reassess Ebola vaccine procurement, trial protocols, or biodefense funding tied to the questioned programs. This would affect directly exposed vaccine makers more than diversified healthcare names.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.